Annu Rev Immunol. 2020 Apr 26; 38(NA):673-703.
PubMed ID: 32340576
Vaccines and broadly neutralizing antibodies for HIV-1 prevention
Stephenson KE, Wagh K, Korber B, Barouch DH
Development of improved approaches for HIV-1 prevention will likely be required for a durable end to the global AIDS pandemic. Recent advances in preclinical studies and early phase clinical trials offer renewed promise for immunologic strategies for blocking acquisition of HIV-1 infection. Clinical trials are currently underway to evaluate the efficacy of two vaccine candidates and a broadly neutralizing antibody (bNAb) to prevent HIV-1 infection in humans. However, the vast diversity of HIV-1 is a major challenge for both active and passive immunization. Here we review current immunologic strategies for HIV-1 prevention, with a focus on current and next-generation vaccines and bNAbs.
With the publicly available data in the CAVD DataSpace we can
Learn about studies, products, assays, antibodies, and publications,
Find subjects with common characteristics,
Plot assay results across studies and years of research, and
Compare monoclonal antibodies and their neutralization curves.
Data are also accessible via DataSpaceR, our R API.
Sign in to see full information about this publication and to download study data when available.